China Resources Double-Crane Pharmaceutical Co.,Ltd.(600062),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

600062 China Resources Double-Crane Pharmaceutical Co.,Ltd.

Closed 12-23 15:00:00

18.43

-0.07

-0.38%

High18.55	Low18.43	Vol3.41M
Open18.51	D1 Closing18.50	Amplitude0.65%
Mkt Cap19.15B	Tradable Cap19.04B	Total Shares1.04B
T/O63.08M	T/O Rate0.33%	Tradable Shares1.03B
P/B1.69	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"China Resources Double-Crane Pharmaceutical Co.,Ltd.","latestPrice":18.43,"timestamp":1766473200000,"preClose":18.5,"halted":0,"volume":3410395,"delay":0,"changeRate":-0.0038,"floatShares":1033000000,"shares":1039000000,"eps":1.5213,"marketStatus":"Closed","change":-0.07,"latestTime":"12-23 15:00:00","open":18.51,"high":18.55,"low":18.43,"amount":63084600,"amplitude":0.0065,"askPrice":18.44,"askSize":69,"bidPrice":18.43,"bidSize":193,"shortable":0,"etf":0,"ttmEps":1.5213,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":5,"adr":0,"adjPreClose":18.5,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":20.35,"lowLimit":16.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038757509,"isCdr":false,"pbRate":1.69,"roa":"--","peRate":12.114639,"roe":"12.34%","epsLYR":1.5838,"committee":0.381046,"marketValue":19144000000,"turnoverRate":0.0033,"status":1,"floatMarketCap":19038000000},"requestUrl":"/m/hq/s/600062/wiki","defaultTab":"wiki","newsList":[{"id":"1105455813","title":"China Resources Double-Crane's Subsidiary Receives Clinical Trial Approval for DC6001 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1105455813","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105455813?lang=en_us&edition=fundamental","pubTime":"2025-12-23 17:03","pubTimestamp":1766480581,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Double-Crane RunChuang Technology Co., Ltd., recently received the Drug Clinical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","BK0185","BK0239","BK0175","600062","BK0010"],"gpt_icon":0},{"id":"2590318095","title":"China Resources Double-Crane Pharmaceutical's ADHD Capsules Included in China's Insurance Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318095","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590318095?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:29","pubTimestamp":1765265362,"startTime":"0","endTime":"0","summary":"Chinese authorities included the dextromethorphan hydrochloride sustained-release capsules manufactured by China Resources Double-Crane Pharmaceutical  subsidiary Henan Zhongshuai Pharmaceutical in the country's national insurance drug catalog.The drug is used as a psychostimulant for attention deficit hyperactivity disorder and nodular disorders in children aged 6 and above, according to a Tuesday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADHD","BK4139","BK0185","BK0010","ABVC","BK0188","BK0028","BK0239","BK0175","600062"],"gpt_icon":0},{"id":"1153124720","title":"China Resources Double-Crane Pharmaceutical (600062.SH): Dexmethylphenidate Hydrochloride Extended-Release Capsules Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1153124720","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153124720?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:36","pubTimestamp":1765186573,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Henan Zhongshuai Medicine...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0010","BK0185","BK0188","BK0239","BK0028","600062"],"gpt_icon":0},{"id":"2588089226","title":"CR Double-Crane Pharmaceutical Subsidiary Gets Supplementary Approval for Type 2 Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2588089226","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588089226?lang=en_us&edition=fundamental","pubTime":"2025-12-02 13:06","pubTimestamp":1764652001,"startTime":"0","endTime":"0","summary":"Chinese drug regulators granted China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Shuanghe Tianan Pharmaceutical (Guizhou) supplementary approval for its pioglitazone hydrochloride dispersible tablets.The drug is indicated for the treatment of type 2 diabetes, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0188","BK0028","BK0010","BK0185","600062","BK0175"],"gpt_icon":0},{"id":"1128972090","title":"China Resources Double-Crane Pharmaceutical (600062.SH) Receives Approval for Pioglitazone Hydrochloride Dispersible Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1128972090","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128972090?lang=en_us&edition=fundamental","pubTime":"2025-12-01 17:24","pubTimestamp":1764581056,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug Supplement Approval...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600062","BK0028","BK0188","BK0185","BK0010","BK0175","BK0239"],"gpt_icon":0},{"id":"2586818652","title":"CR Double-Crane Pharma Gets Regulatory Nod for Alternative Hypertension Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586818652","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586818652?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:36","pubTimestamp":1764124588,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  obtained drug registration from China's medical products administrator for bisoprolol fumarate and amlodipine besilate tablets.The product serves as an alternative therapy for hypertension, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0010","BK0239","BK0028","600062","BK0185","BK0188"],"gpt_icon":0},{"id":"1146471163","title":"China Resources Double-Crane Pharmaceutical's Subsidiary Obtains Drug Registration Certificate for Bisoprolol Amlodipine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1146471163","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146471163?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:58","pubTimestamp":1764061116,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, CR Sike Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0185","BK0175","BK0239","MXPmain","BK0028","EWW","BK0188","600062","BK0010"],"gpt_icon":0},{"id":"2584946219","title":"China Approves CR Double-Crane Pharmaceutical Subsidiary's Anti-Seizure Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946219","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946219?lang=en_us&edition=fundamental","pubTime":"2025-11-19 12:36","pubTimestamp":1763526968,"startTime":"0","endTime":"0","summary":"Chinese drug regulators approved the oxcarbazepine tablets produced by China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Hunan Xiangzhong Pharmaceutical, according to a Wednesday fil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0188","BK0239","BK0010","BK0185","BK0028","600062"],"gpt_icon":0},{"id":"1191074244","title":"China Resources Double-Crane Pharmaceutical (600062.SH) Obtains Drug Registration Certificate for Oxcarbazepine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1191074244","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191074244?lang=en_us&edition=fundamental","pubTime":"2025-11-18 17:10","pubTimestamp":1763457025,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Hunan Xiangzhong Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0185","BK0175","BK0188","600062","BK0010","BK0239","BK0028"],"gpt_icon":0},{"id":"2583523085","title":"CR Double-Crane Unit Clears GMP Inspection for Diabetes Drug Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523085","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523085?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:34","pubTimestamp":1763094868,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  said its subsidiary Shuanghe Tian'an Pharmaceutical  passed a good manufacturing practice  compliance inspection for its metformin and empagliflozin tablets production line.The inspection was conducted in Guiyang City, Guizhou Province, from Oct. 15 to Oct. 17, according to a Friday filing with the Shanghai Stock Exchange.This marks the first pre-marketing GMP compliance inspection for the drug, which is used to improve glycemic control in adults with type 2 diabetes.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600062","BK0185","BK0175","BK0239","BK0028","BK0188","BK0010"],"gpt_icon":0},{"id":"1138105026","title":"China Resources Double-Crane (600062.SH) Subsidiary TIAN AN Passes GMP Compliance Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=1138105026","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138105026?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:00","pubTimestamp":1763024420,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, TIAN AN Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug GMP Compliance Inspection...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600062","BK0028","BK0188","BK1240","00028","BK0239","BK0175","BK0010","BK0185"],"gpt_icon":0},{"id":"2578693962","title":"CR Double-Crane Pharma's Q3 Profit Rises 7%, Revenue Slips 3%; Shares Up 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578693962","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578693962?lang=en_us&edition=fundamental","pubTime":"2025-10-27 12:01","pubTimestamp":1761537672,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical's  net profit attributable to shareholders in the third quarter rose 6.7% year on year to 374 million yuan, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's shares rose over 1% during Monday morning trade.Earnings per share in the same quarter increased 7.2% year on year to 0.36 yuan.Operating revenue slipped 3% from a year earlier to 2.54 billion yuan.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0188","600062","BK0010","BK0028","BK0175","BK0185"],"gpt_icon":0},{"id":"2577599282","title":"BRIEF-China Resources Double-Crane Pharmaceutical Q3 Net Profit Up 6.7% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2577599282","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577599282?lang=en_us&edition=fundamental","pubTime":"2025-10-24 17:16","pubTimestamp":1761297395,"startTime":"0","endTime":"0","summary":"BRIEF-China Resources Double-Crane Pharmaceutical Q3 Net Profit Up 6.7% Y/YOct 24 (Reuters) - China Resources Double-Crane Pharmaceutical Co Ltd 600062.SS:SAYS Q3 NET PROFIT UP 6.7% Y/YSource textFurther company coverage: 600062.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nL4N3W50Q1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","600062","BK0185","BK0028","BK0010","BK0239","BK0175"],"gpt_icon":0},{"id":"2577596771","title":"China Resources Pharmaceutical - 9M Net Profit for China Resources Double-Crane Pharmaceutical RMB1.39 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2577596771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577596771?lang=en_us&edition=fundamental","pubTime":"2025-10-24 17:14","pubTimestamp":1761297240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W5261:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK0028","BK1570","BK0175","BK0239","BK0185","BK0010","03320","600062","BK0188"],"gpt_icon":0},{"id":"1172097305","title":"Shares of \"Traditional Chinese Medicine Leader\" Pientzehuang Drop 35% from Highs as Q3 Profit Continues to Plummet","url":"https://stock-news.laohu8.com/highlight/detail?id=1172097305","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172097305?lang=en_us&edition=fundamental","pubTime":"2025-10-22 18:11","pubTimestamp":1761127889,"startTime":"0","endTime":"0","summary":"Pientzehuang's third-quarter report has been released, revealing a substantial decline in net profit for two consecutive quarters. On October 22, the company's stock price fell to 180 yuan per share,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300436","601377","BK0010","LU0264606111.USD","BK0183","LU1328615791.USD","LU0572939691.SGD","600436","BK0250","BK0012","BK0196","LU1048596156.SGD","600739","600062","BK0028","BK0175","LU0572940350.SGD","BK0276","BK0074","BK0187","LU0821914370.USD","601166","BK0015","BK0144","BK0188","LU1781817850.SGD","BK0185","BK0239","LU1580142542.USD","BK0278"],"gpt_icon":0},{"id":"2577305817","title":"CR Double-Crane Pharmaceutical's Unit Gets Registration Certificate for Alfacalcidol Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2577305817","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577305817?lang=en_us&edition=fundamental","pubTime":"2025-10-21 12:15","pubTimestamp":1761020116,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical's  unit, Beijing Wanhui Double Crane Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its alfacalcidol soft capsules, according to a Tuesday disclosure on the Shanghai bourse.The drug is used for the treatment of calcium metabolism disorders.The cumulative investment for the research and development of the drug amounted to 4.9 million yuan.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","600062","BK0239","BK0185","BK0010","BK0028","BK0188"],"gpt_icon":0},{"id":"1147278412","title":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) Subsidiary Receives Drug Registration Certificate for Alfacalcidol Soft Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=1147278412","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147278412?lang=en_us&edition=fundamental","pubTime":"2025-10-20 17:34","pubTimestamp":1760952877,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its wholly-owned subsidiary, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd. (\"Wanhui Double-Crane\"), has...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0185","BK0028","600062","BK0239","BK0175","BK0188","BK0010"],"gpt_icon":0},{"id":"2571392970","title":"CR Double-Crane Pharma's Subsidiary Gets Registration Certificate for Bosentan Dispersible Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2571392970","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571392970?lang=en_us&edition=fundamental","pubTime":"2025-09-30 12:31","pubTimestamp":1759206688,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical's  subsidiary, CR Double-Crane Limin Pharmaceutical , received a drug registration certificate for bosentan dispersible tablets, according to a Shanghai bourse filing on Tuesday.The pharmaceutical company invested 8.4 million yuan into the research and development of the drug, which was developed to treat pulmonary arterial hypertension.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600062","BK0175","BK0185","BK0188","BK0028","BK0010","BK0239"],"gpt_icon":0},{"id":"1123961361","title":"China Resources Double-Crane Pharmaceutical (600062.SH) Subsidiary Receives Drug Registration Certificate for Bosentan Dispersible Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1123961361","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123961361?lang=en_us&edition=fundamental","pubTime":"2025-09-29 17:58","pubTimestamp":1759139914,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH) announced that its wholly-owned subsidiary, Huarun Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. (\"Shuanghe Limin\"), has recently...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0010","BK0175","BK0028","600062","BK0185","BK0239","BK0188"],"gpt_icon":0},{"id":"2568080451","title":"CR Double-Crane Obtains Registration for Cardiac Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2568080451","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568080451?lang=en_us&edition=fundamental","pubTime":"2025-09-17 12:42","pubTimestamp":1758084163,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  subsidiary Anhui Double-Crane obtained drug registration from China's medical products administrator for tirofiban hydrochloride and sodium chloride injection.The drug is an antiplatelet aggregation drug for acute coronary syndrome and acute myocardial infarction patients, according to a filing with the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0185","BK0188","600062","BK0028","BK0239","BK0175","BK0010"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","stockEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":-0.0043},{"period":"3month","weight":-0.0213},{"period":"6month","weight":0.0171},{"period":"1year","weight":-0.0403},{"period":"ytd","weight":-0.0456}],"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","perCapita":"17894股","boardName":"医药制造业","registeredCapital":"103875万元","compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"survey":"　　华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。","serverTime":1766517652432,"listedPrice":6.69,"stockholders":"57726人(较上一季度增加0.51%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"China Resources Double-Crane Pharmaceutical Co.,Ltd.(600062),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest China Resources Double-Crane Pharmaceutical Co.,Ltd.(600062) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"China Resources Double-Crane Pharmaceutical Co.,Ltd.,600062,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票老虎,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票老虎国际,China Resources Double-Crane Pharmaceutical Co.,Ltd.行情,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票行情,China Resources Double-Crane Pharmaceutical Co.,Ltd.股价,China Resources Double-Crane Pharmaceutical Co.,Ltd.股市,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票价格,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票交易,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票购买,China Resources Double-Crane Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"China Resources Double-Crane Pharmaceutical Co.,Ltd.(600062),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest China Resources Double-Crane Pharmaceutical Co.,Ltd.(600062) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}